Search Results
Results 501 - 550 of 1726
< 6 7 8 9 10 11 12 13 14 15 16 >
Fischler Björn - - 2007
OBJECTIVES: To study the hepatitis B-specific T cell-mediated immune response in chronically infected children and adolescents. PATIENTS AND METHODS: In all, 36 HBsAg-positive patients, 2 to 19 years old, were included. There were 9 HBeAg-positive patients with normal levels of alanine aminotransferase (ALT) (group 1), 18 HBeAg-positive patients with elevated ...
Pensi Tripati - - 2007
To assess efficacy and safety of fixed-dose combination (FDC) of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV- infection, it was administered in the form of oral suspension (Group-A) or dispersible tablet (Group-B). Assessment of improvement in symptoms, CD4 count and adverse drug reactions was done every three ...
Rajasekaran Sikhamani - - 2007
OBJECTIVES: To study the incidence and risk factors for failure of treatment with antiretroviral therapy among adults in the national treatment program in India, and to estimate the possible number of persons living with human immunodeficiency virus (HIV) who will need a second-line treatment regimen in the next 3 and ...
Martin Kari A - - 2007
OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) are used to treat interferon-associated depression in patients receiving hepatitis C virus therapy. Prior studies have cautioned against the combined use of SSRIs and interferon due to increased risk of hemorrhage. Given the morbidity of depression and its impact on interferon compliance, we sought ...
Tam L W Y - - 2007
OBJECTIVES: In 2003, the World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) introduced the '3 by 5 Initiative' to treat 3 million individuals by the end of 2005. This study evaluates the time to treatment termination, viral load suppression, and detection of drug resistance among antiretroviral-naïve ...
Wahjoeningsih Sri - - 2007
The purpose of this study was to evaluate the anaesthetic technique for Caesarean section which was appropriate for the clinical situation. This retrospective study was conducted on 240 patients undergoing Caesarean section with indications of foetal distress during a 3-year period (2002-2004). The data were reviewed from the patient's medical ...
Vanni T T Departamento de Clínica Médica, Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, - - 2007
Since there are some concerns about the effectiveness of highly active antiretroviral therapy in developing countries, we compared the initial combination antiretroviral therapy with zidovudine and lamivudine plus either nelfinavir or efavirenz at a university-based outpatient service in Brazil. This was a retrospective comparative cohort study carried out in a ...
Nomura Hideyuki H The Center for Liver Diseases, Shin-Kokura Hospital, Kitakyushu City, - - 2007
The objective of this study was to examine the efficacy and safety of low dose long-term interferon (IFN) therapy in aged patients with chronic hepatitis C genotype 1. The IFN therapy was performed in Shin-Kokura Hospital on 44 patients aged 60 or older with chronic hepatitis C. All patients had ...
Camerini Roberto - - 2007
Despite the use of combination therapy with pegylated interferon alpha2a (peg-IFN-alpha2a) + Ribavirin, a large proportion of patients with chronic hepatitis C (CHC) remain unresponsive to treatment. Thymosin alpha 1 (Talpha1) is an immunomodulator, which displays immunological and antiviral activities against hepatitis C virus (HCV) in preclinical clinical settings. The ...
Einstein Mark H MH Albert Einstein College of Medicine, and Albert Einstein Cancer Center, Bronx, NY 10461, USA. - - 2007
SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7. This trial was designed to evaluate the efficacy and toxicities of HspE7 in women with ...
Fujiwara Kenji K Yokohama Rosai Hospital, Yokohama, - - 2007
The efficacy and safety of double filtration plasmapheresis (DFPP) plus interferon (IFN) combination therapy were compared with those of IFN therapy alone in 193 chronic hepatitis C patients having a high hepatitis C virus ribonucleic acid load of difficult-to-treat genotype 1b. All patients received either interferon alpha-2b (IFN-alpha-2b) monotherapy or ...
Arora R S - - 2007
We describe a cohort of 14 Hurler-Scheie patients homozygous for the p.Leu490Pro missense mutation in the alpha-L-iduronidase gene. Now based in the UK, they are all of Pakistani/Kashmiri descent; 64% were female; 11/14 (79%) had a sibling or cousin with MPS I and the parents are consanguineous in all cases. ...
Moltó José - - 2007
OBJECTIVES: The efficacy and safety of lopinavir/ritonavir monotherapy has been explored with promising results in well-controlled, randomized clinical trials. However, less information about its clinical usefulness in routine clinical practice is currently available. The objective of this study was to assess the effectiveness and safety of monotherapy with lopinavir/ritonavir as ...
Manna Laura - - 2008
A real-time PCR assay was exploited for monitoring the Leishmania DNA load in different tissues from 18 naturally-infected dogs before and after treatment with a combination of meglumine antimoniate (100mg/kg/day, subcutaneously) and allopurinol (10mg/kg/day, orally) for 30 days. After the combined therapy, allopurinol was continued at the same dose until ...
Fontanges Thierry - - 2007
OBJECTIVES: Combination therapy using peginterferon alfa-2a (40 kD) plus ribavirin achieves viral eradication in nearly 60% of patients with chronic hepatitis C viral infection. However, because of the numerous side effects, use of the combination regimen might be restricted for patients consulting private practitioners specialized in hepatogastroenterology. PATIENTS AND METHOD: ...
Jousse-Joulin Sandrine - - 2007
INTRODUCTION: Atypical mycobacteria are environmental organisms that cause opportunistic infections in humans. CASE REPORT: A 50-year-old electronics engineer sought advice about starting TNFalpha antagonist therapy for ankylosing spondylitis. Disease duration was 23 years and current treatment was methylprednisolone 4 mg/d. Atypical skin lesions and knee arthritis were noted. Fluid aspirated ...
Diazgranados Carlos A - - 2007
OBJECTIVE: To estimate the rate of optimal response to antiretroviral therapy and its predictors in Colombia. METHODS: A retrospective cohort study was performed. The medical records of all patients at three major HIV clinics in different areas of Colombia, South America, were reviewed. Eligible patients met the following criteria: (1) ...
Kuboki Makoto - - 2007
BACKGROUND: The efficacy and safety of peginterferon alpha-2a (40 KD) (peg-IFNalpha-2a) plus ribavirin has not been reported for Japanese patients with chronic hepatitis C. The aim of this study was to evaluate this combination in treatment-naïve patients and in non-responders or relapsers to interferon monotherapy. METHODS: Overall, 201 treatment-naïve patients ...
Mallolas J - - 2007
BACKGROUND: The addition of a low dose of ritonavir to protease inhibitors (PIs) has become a widespread strategy to improve PI pharmacokinetics. As resistance is a major barrier to long-term suppression, in salvage therapy genotype and/or phenotype scoring is currently used to predict the response. We evaluated the relationship between ...
Kulo─člu Zarife - - 2007
AIM: To evaluate the height and weight patterns of children with chronic hepatitis B (CHB) with and without treatment. METHODS: Thirty-four patients with immunoactive CHB randomly assigned to receive interferon-alpha2a (IFN) (5 mIU/m2, 6 months, group I) or IFN (same dose and duration) plus lamivudine (4 mg/kg/day, 24 months) (group ...
van Lunzen J - - 2007
OBJECTIVE: The aim of the study was to assess the frequency of the concurrent use of gastric acid-reducing agents among HIV-1-infected patients treated with highly active antiretroviral therapy (HAART) combinations. METHODS: An anonymous, semistructured, self-administered questionnaire was consecutively distributed among HIV-1-infected patients at routine visits to specialized HIV clinics. The ...
Cassetti Isabel I Fundacion Centro Estudios Infectologicos, Buenos Aires, - - 2007
Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) and an ongoing additional 336-week open-label extension phase. Patients in Brazil, Argentina, and the Dominican Republic who completed the 144-week double-blind phase ...
Haque Tanzina - - 2007
We present the results of a multicenter clinical trial using Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) generated from EBV-seropositive blood donors to treat patients with EBV-positive posttransplantation lymphoproliferative disease (PTLD) on the basis of the best HLA match and specific in vitro cytotoxicity. Thirty-three PTLD patients who had failed ...
Gatell Jose - - 2007
BACKGROUND: Atazanavir is a once-daily protease inhibitor (PI) for the treatment of human immunodeficiency virus (HIV) infection that has previously been studied in cohorts of treatment-naive and treatment-experienced patients. Limited data are available on the usefulness of switching from a PI-based regimen to a regimen based on a different PI, ...
Gulick Roy M RM Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA. - - 2007
To compare a quadruple-nucleoside with an efavirenz-containing regimen for treatment of HIV-1 infection. A randomized, open-label study of the AIDS Clinical Trials Group (ACTG). Subjects receiving zidovudine/lamivudine/abacavir on ACTG 5095 with HIV-1 RNA less than 200 copies/ml were randomly assigned to intensify either with tenofovir or efavirenz. Subjects were followed ...
Akyildiz Murat - - 2007
We studied clinical and laboratory effects of 3 months of lamivudine with adefovir combination and adefovir dipivoxil (AD) alone in the treatment of patients with lamivudine-resistant hepatitis B virus (HBV) infection. Eligible patients were hepatitis B surface antigen-positive men and women with compensated liver disease who were given lamivudine at ...
Clotet Bonaventura - - 2007
The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies aim to evaluate efficacy and safety of darunavir in combination with low-dose ritonavir in treatment-experienced HIV-1-infected patients. We did a pooled subgroup analysis to update results at week 48 for patients receiving the recommended dose of darunavir-ritonavir compared with ...
Neff Guy W - - 2007
Conventional therapy to prevent HBV recurrence in liver transplant (LTx) recipients consists of Hepatitis B Immune Globulin (HBIg). The aim of this review is to investigate the safety and efficacy of converting HBIg and LAM therapy to ADV and LAM therapy. A retrospective review involving all liver transplant patients with ...
Fischer Joerg - - 2007
BACKGROUND: Most of the new fillers used for soft tissue augmentation in aesthetic dermatology are considered well tolerated, but very little data are available on their long-term tolerability, especially in patients receiving immunomodulatory therapy. OBSERVATIONS: A 48-year-old woman presented with disfiguring facial edema 10 weeks after she began antiviral therapy ...
Karlström Olle - - 2007
OBJECTIVE: To investigate the feasibility of ritonavir-boosted atazanavir monotherapy in HIV-1-infected patients with stable antiretroviral therapy (ART). DESIGN: Single-armed single-center pilot trial. METHODS: Adult HIV-1-infected patients, without protease inhibitor (PI) experience, were eligible if they had maintained a viral load <20 copies/mL for a minimum of 12 months on conventional ...
Chiou Tzeon-Jye - - 2007
The potential synergistic anti-myeloma effect for thalidomide combining with interferon alpha was not yet clear clinically. From March 2001 to January 2004, a total of 28 heavily pretreated multiple myleoma (MM) patients were enrolled in this open-labeled, randomized Phase II study. Patients with refractory MM were randomized to receive either ...
Huerva Valentín - - 2007
AIMS: The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure. METHODS: This study is a case report description. RESULTS: An 81-year-old man ...
Falco Laura A - - 2007
BACKGROUND: This article describes the differential diagnosis of conjunctival papillomas and reviews the treatment options with a focus on the new topical interferon alpha 2 beta therapy. CASE: A 45-year-old white man presented with a red right eye of approximately 6 months' duration. The lesion was suspicious and suggestive of ...
Roussou Maria - - 2007
There are limited data regarding the long term follow up after thalidomide based regimen and the outcome of patients when they progress and they receive further treatment. We reassessed our original series of 43 patients with previously treated multiple myeloma who had received a pulsed cyclophosphamide, thalidomide, dexamethasone (CTD) regimen. ...
Le Moing V - - 2007
BACKGROUND: The increase in CD4 count may reach a plateau after some duration of virological response to highly active antiretroviral therapy (HAART). METHODS: A total of 1281 HIV-infected patients initiating HAART were enrolled in the AntiPROtease (APROCO) cohort. We investigated determinants of increase in CD4 count using longitudinal mixed models ...
Hart E - - 2007
OBJECTIVES: The aim of the study was to explore the factors surrounding modification of the first antiretroviral (ARV) regimen where drug switch occurred 3 months or more after initiation. Reference was made to the British HIV Association (BHIVA) guidelines on HIV management. METHODS: A case note and questionnaire-based audit was ...
Vrouenraets Saskia M E SM IATEC, Pietersbergweg 9, 1105 BM Amsterdam, The Netherlands. - - 2007
Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combination regimens is good, as has been demonstrated in ...
Riley Thomas R TR - - 2007
In this report, we describe five cases of chronic hepatitis C that have been treated with the combination of amantadine and ribavirin for an average of 44 months, emphasizing one case where the patient showed improvement in liver biopsy after treatment, worsening on removal, then a repeated improvement with re-initiation. ...
Wilson Matthew W - - 2007
PURPOSE: To report the use of a combination of low-dose cyclophosphamide and interferon alfa 2a (IFNalpha2a) for the treatment of orbital juvenile capillary hemangioma. DESIGN: Retrospective case series. PARTICIPANTS: Five patients with juvenile capillary hemangiomas of the orbit. METHODS: Five patients with a median age of 9 weeks presented with ...
Vilar Gomez Eduardo - - 2007
BACKGROUND: The pathogenesis of chronic hepatitis C (CHC) is associated to severe oxidative stress that leads to necro-inflammation and progression of fibrosis. Previous trials suggested that antioxidative therapy may have a beneficial effect. We evaluated the efficacy and safety of Viusid in combination with interferon alpha-2b (IFN alpha-2b) and ribavirin ...
Kaymakoglu Sabahattin - - 2007
We sought to evaluate the long-term results of interferon-alpha (IFN-alpha) therapy in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Eighty HBeAg-negative naive patients (62 men; mean age, 39.9 years) who received IFN-alpha for 6 months were studied. Alanine aminotransferase normalization with undetectable HBV-DNA by molecular hybridization was ...
Gheorghe Liana - - 2007
BACKGROUND AND AIM: Increasing evidence to date highlights that individualized treatment regimens with pegylated interferon (PegIFN) and ribavirin represent a better approach for patients nowadays showing negative predictive factors for sustained virological response. The aims of this study were to assess the rate of early (EVR) and sustained virological response ...
Hehlmann Rüdiger - - 2007
Early allogeneic hematopoietic stem cell transplantation (HSCT) has been proposed as primary treatment modality for patients with chronic myeloid leukemia (CML). This concept has been challenged by transplantation mortality and improved drug therapy. In a randomized study, primary HSCT and best available drug treatment (IFN based) were compared in newly ...
Zivadinov R - - 2007
BACKGROUND: Brain atrophy, as assessed by magnetic resonance imaging (MRI), has been correlated with disability in patients with multiple sclerosis (MS). Recent evidence indicates that both white matter (WM) and gray matter (GM) are subject to atrophy in patients with MS. Although neurological deficiencies in MS are primarily due to ...
Sackeim Harold A - - 2007
This study characterized the durability of improvement in patients who responded early or late while receiving vagus nerve stimulation (VNS). In both a pilot and pivotal study, patients were identified who had at least a 50% reduction in symptom scores 3 months (early responders) or 12 months (late responders) after ...
Safdar A - - 2007
Pneumocandins have concentration-dependent antifungal activity and higher dose of caspofungin (HD-CAP) in combination with other licensed antifungal therapy (OLAT) may improve response. Thirty-four patients who received HD-CAP were compared with 63 patients who received standard dose (SD)-CAP. There were no differences between the groups in either patient or disease characteristics. ...
Libamba Edwin - - 2007
PROBLEM: Many resource-poor countries have started scaling up antiretroviral therapy (ART). While reports from individual clinics point to successful implementation, there is limited information about progress in government institutions at a national level. APPROACH: Malawi started national ART scale-up in 2004 using a structured approach. There is a focus on ...
Fartoux Laetitia - - 2007
BACKGROUND & AIMS: The impact of interferon (IFN) treatment on the occurrence of complications related to hepatitis C virus (HCV)-related cirrhosis is debated because the majority of studies are retrospective. We designed a randomized controlled trial comparing the efficacy of prolonged IFN alfa-2a treatment vs nontreatment on complication-free survival in ...
Papeix C - - 2007
To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon ...
Witthoeft Th T University Hospital Schleswig-Holstein Campus Luebeck, Department of Medicine I, Division of Gastroenterology, Luebeck 23538, Germany. - - 2007
To investigate the use of high dose consensus-interferon in combination with ribavirin in former iv drug users infected with hepatitis C. We started, before pegylated (PEG)-interferons were available, an open-label study to investigate the efficacy and tolerability of high dose induction therapy with consensus interferon (CIFN) and ribavirin in treatment ...
< 6 7 8 9 10 11 12 13 14 15 16 >